On June 29, 2026 the CSI Pharmaceutical and Medical Device Innovation Index jumped 5.85%, pulling the Ping An Medical Innovation ETF (516820) up a matching 5.84% to 0.33 yuan. The rally was led by heavy‑weight names such as 3S Guojian (+20%), Eli Lilly (+14.8%) and Haisik (+10%), while other innovators like Pharmaron and Hengrui Medicine also climbed. A new report from the China Federation of Logistics and Purchasing shows China’s medical‑device sector is on a roll. By mid‑June the country had approved a record 431 innovative devices, with 40 fresh approvals in 2026 alone. The industry’s market size reached roughly 1.2 trillion yuan in 2025, posting a modest 1.12% year‑on‑year growth that signals steady, healthy expansion. Analysts at Huafu Securities warn that firms relying on a single product may feel the squeeze of centralized procurement, urging diversification into upstream tech like optics and materials, or cutting‑edge fields such as brain‑computer interfaces and surgical robots. The recent approval of BrainCo’s invasive BCI device and its pending IPO on the Sci‑Tech Innovation Board could spark a sector‑wide rally. The Ping An ETF mirrors the CSI index, which selects 30 profitable, high‑growth pharma and device companies. Its top ten holdings—WuXi AppTec, Hengrui Medicine, Mindray, Xinheda, Aier Eye Hospital, Yunnan Baiyao, Pharmaron, Huadong Medicine, Eli Lilly and Dong’e Ejiao—account for nearly 65% of the index, underscoring the concentration of innovation in a handful of market leaders.
Read moreOn June 29, 2026 the Taikang Medical Health ETF (code 159760) jumped nearly 6%, trading at a 5.78% gain with a turnover of 3.56% and a volume of about 2.79 million yuan. The fund mirrors the Guosen Public Health and Medical Health Index (980016), which surged 6.39% in the same session. Leading the rally were Sansheng Guojian (+20%), Rongchang Bio (+19.9%), Junshi Bio (+15.2%) and several other health‑care names. A fresh report from the China Federation of Logistics and Purchasing titled “China Medical Device Supply Chain Development Report (2026)” highlighted a boom in innovative medical devices. By June 18, 2026 China had approved a total of 431 novel devices, with 40 new approvals recorded this year – a historic peak that underscores the sector’s creative vigor and technical breakthroughs. The industry’s market size reached roughly 1.2 trillion yuan in 2025, posting a modest 1.12% year‑on‑year growth. The brain‑computer‑interface arena also hit a milestone: Bonsecours filed for a STAR Market IPO and received approval for its invasive product NEO‑ONE SCI, the world’s first device of its kind. Analysts see immediate use in medical rehabilitation and, over the longer term, potential expansion into trillion‑yuan consumer and tech markets such as human‑computer interaction and consciousness control. From a valuation standpoint, the index’s trailing‑12‑month PE sits at just 25.68×, placing it in the bottom 2.3% of its historical range – a rare low‑price opportunity for investors interested in China’s fast‑growing health‑care sector.
Read more